Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

Clinical trial NCT06351527 · RECRUITING

Trial details

NCT number

NCT06351527

Sponsor

InnoCare Pharma Inc.

Status

RECRUITING

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2024-04-23

Primary completion

2027-06-25

Enrollment

78

View on ClinicalTrials.gov